Cerivastatin: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 49: Line 49:
}}
}}


{{CMG}}{{SS}}
{{CMG}}  {{AE}}{{SS}}


'''Cerivastatin''' (brand names: '''Baycol''', '''Lipobay''') is a synthetic member of the class of [[statin]]s used to lower [[cholesterol]] and prevent [[cardiovascular disease]]. It was marketed by the [[pharmaceutical company]] [[Bayer|Bayer A.G.]] in the late 1990s, competing with [[Pfizer Inc.|Pfizer]]'s highly successful [[atorvastatin]] (Lipitor). Cerivastatin was voluntarily withdrawn from the market worldwide in 2001, due to reports of fatal [[rhabdomyolysis]].
'''Cerivastatin''' (brand names: '''Baycol''', '''Lipobay''') is a synthetic member of the class of [[statin]]s used to lower [[cholesterol]] and prevent [[cardiovascular disease]]. It was marketed by the [[pharmaceutical company]] [[Bayer|Bayer A.G.]] in the late 1990s, competing with [[Pfizer Inc.|Pfizer]]'s highly successful [[atorvastatin]] (Lipitor). Cerivastatin was voluntarily withdrawn from the market worldwide in 2001, due to reports of fatal [[rhabdomyolysis]].
Line 63: Line 63:
[[Category:Statins]]
[[Category:Statins]]
[[Category:Withdrawn drugs]]
[[Category:Withdrawn drugs]]
[[Category:Diols]]
[[Category:Carboxylic acids]]
[[Category:Carboxylic acids]]
[[Category:Organofluorides]]
[[Category:Organofluorides]]
[[Category:Ethers]]
[[Category:Ethers]]
[[Category:Cardiovascular Drugs]][[Category:Drugs]]
[[Category:Cardiovascular Drugs]][[Category:Drugs]]

Revision as of 20:54, 23 July 2014

Cerivastatin
Clinical data
Pregnancy
category
  • AU: D
ATC code
Legal status
Legal status
  • Withdrawn from market
Pharmacokinetic data
Elimination half-life2–3 hours
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC26H34FNO5
Molar mass459.55 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Cerivastatin (brand names: Baycol, Lipobay) is a synthetic member of the class of statins used to lower cholesterol and prevent cardiovascular disease. It was marketed by the pharmaceutical company Bayer A.G. in the late 1990s, competing with Pfizer's highly successful atorvastatin (Lipitor). Cerivastatin was voluntarily withdrawn from the market worldwide in 2001, due to reports of fatal rhabdomyolysis.

During postmarketing surveillance, 52 deaths were reported in patients using cerivastatin, mainly from rhabdomyolysis and its resultant renal failure.[1] Risks were higher in patients using fibrates, mainly gemfibrozil (Lopid), and in patients using the highest (0.8 mg/day) dose of cerivastatin. Bayer A.G. added a contraindication for the concomitant use of cerivastatin and gemfibrozil to the package 18 months after the drug interaction was found.[2] The frequency of deadly cases of rhabdomyolysis with cerivastatin was 16 to 80 times higher than with other statins.[3] Another 385 nonfatal cases of rhabdomyolysis were reported. This put the risk of this (rare) complication at 5-10 times that of the other statins. Cerivastatin also induced myopathy in a dose-dependent manner when administered as monotherapy, but that was revealed only after Bayer was sued and unpublished company documents were opened.[4]

References

  1. ↑ Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001;2:205-207. PMID 11806796.
  2. ↑ Psaty BM, Furberg CD, Ray WA, Weiss NS (2004). "Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis". JAMA. 292 (21): 2622–31. doi:10.1001/jama.292.21.2622. PMID 15572720.
  3. ↑ Zeitlinger M, Müller M (2003). "[Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis]". Wien Med Wochenschr (in German). 153 (11–12): 250–4. doi:10.1046/j.1563-258X.2003.03029.x. PMID 12879633.
  4. ↑ Saito M, Hirata-Koizumi M, Miyake S, Hasegawa R (2005). "[Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States]". Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku (in Japanese) (123): 41–5. PMID 16541751.

Template:Statins

Retrieved from "https://www.wikidoc.org/index.php?title=Cerivastatin&oldid=999946"